Purple Biotech (PPBT) - Total Assets
Based on the latest financial reports, Purple Biotech (PPBT) holds total assets worth $14.17 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Purple Biotech - Total Assets Trend (2013–2025)
This chart illustrates how Purple Biotech's total assets have evolved over time, based on quarterly financial data. Also see Purple Biotech market cap and net worth for the company's overall valuation and market capitalisation.
Purple Biotech - Asset Composition Analysis
Current Asset Composition (December 2025)
Purple Biotech's total assets of $14.17 Million consist of 56.2% current assets and 43.9% non-current assets. Review PPBT total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.6% |
| Accounts Receivable | $155.00K | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.36 Million | 41.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Purple Biotech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Purple Biotech (PPBT) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Purple Biotech's current assets represent 56.2% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 49.6% of total assets in 2025, down from 62.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 41.9% of total assets.
Purple Biotech Competitors by Total Assets
Key competitors of Purple Biotech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Purple Biotech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.70 | 2.88 | 13.78 |
| Quick Ratio | 3.70 | 2.88 | 13.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.81 Million | $4.12 Million | $43.77 Million |
Purple Biotech - Advanced Valuation Insights
This section examines the relationship between Purple Biotech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -52.6% |
| Total Assets | $17.57 Million |
| Market Capitalization | $2.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Purple Biotech's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Purple Biotech's assets decreased by 52.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Purple Biotech (2013–2025)
The table below shows the annual total assets of Purple Biotech from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $17.57 Million | -52.56% |
| 2024-12-31 | $37.04 Million | -16.40% |
| 2023-12-31 | $44.30 Million | -18.89% |
| 2022-12-31 | $54.62 Million | -22.19% |
| 2021-12-31 | $70.20 Million | -16.23% |
| 2020-12-31 | $83.80 Million | +469.39% |
| 2019-12-31 | $14.72 Million | -0.03% |
| 2018-12-31 | $14.72 Million | +3.81% |
| 2017-12-31 | $14.18 Million | -4.90% |
| 2016-12-31 | $14.91 Million | +37.94% |
| 2015-12-31 | $10.81 Million | +514.67% |
| 2014-12-31 | $1.76 Million | +465.59% |
| 2013-12-31 | $311.00K | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more